Market reaction
Regeneron Pharmaceuticals shares fell 5.24% to $693.43 on Wednesday following the firm’s first-quarter results that showed an overall reduction in sales of its eye-disease treatment Eylea. The company disclosed that Eylea revenue declined 10% in the quarter, and investors reacted to several product-specific and regulatory developments the company reported.
Eylea sales details
Regeneron reported Eylea sales of $941 million for the quarter. The company said that its higher-dose formulation, Eylea HD, was particularly affected by lower wholesaler inventory levels. Management attributed the decline in Eylea HD volumes to those reduced distributor inventories.
Regulatory status for pre-filled syringe version
Regeneron said the U.S. Food and Drug Administration did not act by its April 2026 target date on the company’s application related to a second contract manufacturer for the pre-filled syringe presentation of Eylea HD. The timing of the agency’s action, or lack thereof by that target date, was highlighted in the company’s disclosure.
Pipeline update and analyst view
RBC Capital Markets pointed to several items as contributing to the stock’s decline: weaker-than-expected sales of Eylea HD, regulatory complications around the pre-filled syringe version of the drug, and a separate development in which an experimental lung cancer drug combination will not move forward to late-stage trials. Those factors were explicitly cited by RBC in explaining the market reaction.
Earnings performance
On the earnings front, Regeneron reported adjusted earnings of $9.47 per share for the first quarter, topping analysts’ consensus of $8.94 per share. The earnings result was a beat versus expectations even as product revenue for Eylea declined.
Observed uncertainties
The company’s commentary and analyst notes make clear there are outstanding questions around the timing of regulatory action for the pre-filled syringe supplier application, the near-term sales trajectory for Eylea HD amid inventory dynamics, and the progress of the company’s clinical programs, given that the specific lung cancer combination noted will not advance to late-stage testing. Those items were central to the market’s assessment.